Radiomics and theranostics with molecular and metabolic probes in prostate cancer: towards a personalised approach.

F-FDG, provided valuable information to select patients who are more likely to benefit from RLT and getting information on PCa grade of differentiation and aggressiveness. In spite of its high potential, PET-radiomics for PCa is still at an embryonic phase and needs further validation.